Biotech Values

[ghmm]

HALO:

I don't follow them closely since I sold out with that caveat their guidance was probably a bit worse (lower revenue, higher burn) than people expected. When I sold out (probably a couple years ago now) they said they would likely not need a financing going forward (Counting the royalty I think they are up to 3 or 4). After the Roche Immunogen royalty rate was announced (and one reason I sold) I began to wonder why their royalty would be higher. The company had said mid single digits with the street saying 5%. Maybe someone who follows them more closely can say if the company has since confirmed that or if in fact its more like 3-4%. The other concern is PEG-PH20 companion diagnostic and I'm not sure where they stand on that. I still like PEG-PH20 though I'm less sure of it than before (I am long NKTR so still have an interest).